免疫チェックポイント阻害薬の市場規模、シェア、成長分析：タイプ別、用途別、流通チャネル別、地域別 - 産業予測 2025～2032年

免疫チェックポイント阻害薬の世界市場規模は2023年に484億7,000万米ドルと評価され、2024年の568億1,000万米ドルから2032年には2,022億2,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは17.2％で成長する見通しです。

メラノーマやホジキンリンパ腫と並んで、肺がん、乳がん、膀胱がん、子宮頸がんなど、さまざまながんの発生率が上昇していることが、免疫チェックポイント阻害薬の採用を後押ししています。カナダがん協会によると、カナダ人の約40％が一生のうちにがんの診断を受け、死亡リスクも大きいことから、効果的な診断・治療ソリューションへの需要が高まっています。特に、新規の免疫チェックポイント阻害薬の研究が進んでいることから、市場は拡大傾向にあります。特に、遺伝子腫瘍の特徴に基づくペムブロリズマブのFDA承認は、標的治療の進歩を浮き彫りにしています。技術の進歩や社会的認知度の向上など課題は山積していますが、免疫チェックポイント阻害薬市場は、特に新興国において力強い成長の可能性を示しており、利害関係者にとって有望な展望を示しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢
• 特許分析

免疫チェックポイント阻害薬市場規模：タイプ別

• 市場概要
• PD-1阻害薬
• PD-L1阻害薬
• CTLA-4阻害薬
• その他

免疫チェックポイント阻害薬市場規模：用途別

• 市場概要
• 肺がん
• 乳がん
• 悪性黒色腫
• 膀胱がん
• ホジキンリンパ腫
• その他

免疫チェックポイント阻害薬市場規模：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

免疫チェックポイント阻害薬市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Bristol-Myers Squibb Company（USA）
• Merck & Co., Inc.（USA）
• F. Hoffmann-La Roche AG（Switzerland）
• Regeneron Pharmaceuticals, Inc.（USA）
• AstraZeneca PLC（UK）
• Eli Lilly and Company（USA）
• Sanofi（France）
• BeiGene Ltd.（China）
• Shanghai Junshi Biosciences Ltd.（China）
• GlaxoSmithKline PLC（UK）
• Immutep Ltd.（Australia）
• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Genentech, Inc.（USA）
• Incyte Corporation（USA）
• MacroGenics, Inc.（USA）
• Agenus Inc.（USA）
• Jiangsu Hengrui Medicine Co., Ltd.（China）
• Innovent Biologics, Inc.（China）
• Daiichi Sankyo Company, Limited（Japan）

結論と提言

Global Immune Checkpoint Inhibitors Market size was valued at USD 48.47 billion in 2023 and is poised to grow from USD 56.81 billion in 2024 to USD 202.22 billion by 2032, growing at a CAGR of 17.2% during the forecast period (2025-2032).

The rising incidence of various cancers, including lung, breast, bladder, and cervical cancers, alongside melanomas and Hodgkin lymphoma, is driving the adoption of immune checkpoint inhibitors. According to the Canadian Cancer Society, approximately 40% of Canadians will receive a cancer diagnosis in their lifetime, with a significant mortality risk, fueling the demand for effective diagnostic and therapeutic solutions. The market is set for expansion, particularly with ongoing research into novel immune checkpoint inhibitors. Notably, pembrolizumab's FDA approval, based on genetic tumor features, highlights progress in targeted treatments. While challenges persist, including technological advancements and increased public awareness, the immune checkpoint inhibitors market demonstrates robust growth potential, especially in emerging economies, indicating a promising outlook for stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immune Checkpoint Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immune Checkpoint Inhibitors Market Segments Analysis

Global Immune Checkpoint Inhibitors Market is segmented by Type, Application, Distribution Channel and region. Based on Type, the market is segmented into PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors and Others. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Melanoma, Bladder Cancer, Hodgkin Lymphoma and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Immune Checkpoint Inhibitors Market

The global immune checkpoint inhibitors market has experienced substantial growth driven by technological innovations and scientific advancements in the field of immunotherapy. In recent years, extensive research has highlighted the essential function of the immune system in fighting cancer, resulting in the creation of therapies that bolster the body's natural immune response to neoplastic cells. As a result, immune checkpoint inhibitors have become a fundamental component of contemporary cancer treatment, specifically targeting and modulating proteins that control immune checkpoints. This evolution in cancer therapy is revolutionizing patient outcomes and expanding the potential for novel treatment options across various malignancies.

Restraints in the Global Immune Checkpoint Inhibitors Market

A major constraint impacting the global immune checkpoint inhibitors market is the steep cost of these therapies. Treatments like pembrolizumab (Keytruda) and nivolumab (Opdivo) carry high price tags due to the extensive investment in research and development, intricate manufacturing methods, and the exorbitant expenses associated with clinical trials. Consequently, a single treatment regimen can amount to tens of thousands of dollars, rendering it unaffordable for numerous patients and healthcare systems, particularly in low- and middle-income nations. This financial burden significantly hampers accessibility to these potentially life-saving therapies for a large segment of the population.

Market Trends of the Global Immune Checkpoint Inhibitors Market

The global immune checkpoint inhibitors market is witnessing significant growth, primarily driven by the rising incidence of cancer, which remains a major health challenge worldwide. As cancer rates continue to surge due to factors such as aging populations and lifestyle changes, the demand for innovative therapies is escalating. Immune checkpoint inhibitors, which have shown promising results in enhancing the immune response against tumors, are becoming essential in oncology treatment regimens. This upward trend is further fueled by ongoing research, the development of novel therapies, and expanding applications in various cancer types, positioning the market for robust expansion in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Immune Checkpoint Inhibitors Market Size by Type & CAGR (2025-2032)

• Market Overview
• PD-1 Inhibitors
• PD-L1 Inhibitors
• CTLA-4 Inhibitors
• Others

Global Immune Checkpoint Inhibitors Market Size by Application & CAGR (2025-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Melanoma
• Bladder Cancer
• Hodgkin Lymphoma
• Others

Global Immune Checkpoint Inhibitors Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Immune Checkpoint Inhibitors Market Size & CAGR (2025-2032)

• North America (Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Junshi Biosciences Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immutep Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agenus Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangsu Hengrui Medicine Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent Biologics, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations